Articles
FEATURED ARTICLES
-
Article
Jul 28, 2022
RNA vaccines are hugely versatile. They can potentially inoculate against any pathogen for which a protein target is known, for example, influenza, chlamydia, HIV-1 (human immunodeficiency virus 1), Ebola and RSV (respiratory syncytial virus). Self-amplifying RNA (saRNA) is a typ... -
Article
Mar 01, 2022
Precision NanoSystems maintains that mRNA and LNP technologies, microfluidics, and distributed manufacturing will revamp vaccine production.
LATEST ARTICLES
-
Article
Dec 08, 2023
Navigating global regulations for RNA-LNP therapeutics with early regulatory strategy and by establishing LNP Manufacturing Partners -
Article
Dec 01, 2023
Analytics and bioassays monitor variables like RNA, LNP composition, polydispersity, particle size, and manufacturing process to accelerate RNA-LNP production. -
Article
Nov 01, 2023
Outsourcing RNA–LNP drug manufacturing accelerates drug development with advanced cGMP technologies, comprehensive analytical testing, and biopharma services. -
Article
Jul 27, 2023
Single-use technology provides a sterile environment, accelerating biopharmaceutical manufacturing of mRNA-LNP drugs with less cleaning and validation needs. -
Article
Jun 05, 2023
Rapidly develop and optimize LNP-based drug delivery systems for clinical applications by accessing diverse range of pre-screened lipid compositions. -
Article
Jan 18, 2023
Lipid Nanoparticles (LNPs) are nanoparticles formed by lipid components that are one of the effective means for mRNA delivery. Although the emergence of variants of COVID-19 has encouraged greater demands for developing mRNA–LNP vaccines, its benefits extend beyond vaccinations t... -
Article
Dec 07, 2022
Limit size behavior, in-line dilution and tangential flow filtration are important process considerations to evaluate and optimize during process development. -
Article
Sep 28, 2022
Nanomedicine offers promising therapeutic solutions for cell and gene therapies, autoimmune diseases, oncology, rare inherited diseases and more. Some new avenues to explore include early disease detection or molecularly tailored treatments for patients who have complex diseases ... -
Article
Sep 28, 2022
The production of RNA lipid nanoparticles (LNPs) such as those used in COVID-19 vaccines involves mixing RNA in an aqueous buffer with lipids dissolved in ethanol to trigger the self-assembly of LNPs. The mixing conditions of the RNA and lipids are crucial to drug product quality... -
Article
Sep 20, 2022
COVID vaccine development has proven that genomic medicines have the potential for faster drug development. Along with potential therapies across screening, prevention, and treatment options, genomic medicines can target the disease-causing gene mutations, offering a more accurat... -
Article
Jun 09, 2022
Scale-up and downstream processing operations can impact the functionality and stability of mRNA-LNPs in vaccine development including COVID-19 vaccines. -
Article
Mar 01, 2022
During development of pharmaceutically-applicable mRNA therapeutics, synthesis, optimization, and formulation must be taken into consideration.
Advanced Search
close- Publications
- Application Notes
- Posters
- Workshops
- Videos & Webinars
- Articles
Browse by Category
-
Application
- Diagnostic and Imaging
- Genetic Medicine
- Hematology
- Metabolic Disorders
- Neuroscience
- Oncology
- Skeletal Disorders
- Targeted Drug Delivery
- Vaccines
- Other Applications
- Cell therapy
-
Formulation
- Liposomes
- Nucleic Acid Lipid Nanoparticles
- Polymeric Nanoparticles
- Other Formulations
-
Payload
- DNA
- microRNA
- mRNA
- siRNA
- Small Molecule Drugs
- Other Payloads
Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.